Tech Company Financing Transactions

Tarveda Therapeutics Funding Round

Tarveda Therapeutics closed a $16 million Series B funding round on 12/18/2012. Investors included NanoDimension, Flagship Pioneering and New Enterprise Associates.

Transaction Overview

Announced On
12/18/2012
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series B
Investors

NanoDimension (Lead Investor)

Flagship Pioneering (Ed Kania)

New Enterprise Associates (Frank Torti)

Proceeds Purpose
Proceeds from the financing will be used to expand Blend's product and business development teams and to advance the company's lead programs through studies to enable filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
134 Coolidge Avenue
Watertown, MA 02472
USA
Email Address
Overview
Tarveda creates Pentarins that are targeted miniature drug conjugates that remain miniature by design to overcome the challenges that limit the efficacy of larger antibody drug conjugates in use and development today.
Profile
Tarveda Therapeutics LinkedIn Company Profile
Social Media
Tarveda Therapeutics Company Twitter Account
Company News
Tarveda Therapeutics News
Facebook
Tarveda Therapeutics on Facebook
YouTube
Tarveda Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Drew Fromkin
  Drew Fromkin LinkedIn Profile  Drew Fromkin Twitter Account  Drew Fromkin News  Drew Fromkin on Facebook
Chief Medical Officer
Leila Alland
  Leila Alland LinkedIn Profile  Leila Alland Twitter Account  Leila Alland News  Leila Alland on Facebook
VP - Bus. Development
Sudha Kadiyala
  Sudha Kadiyala LinkedIn Profile  Sudha Kadiyala Twitter Account  Sudha Kadiyala News  Sudha Kadiyala on Facebook
VP - R & D
Richard Wooster
  Richard Wooster LinkedIn Profile  Richard Wooster Twitter Account  Richard Wooster News  Richard Wooster on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/18/2012: Tau Therapeutics venture capital transaction
Next: 12/19/2012: EXAI venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary